A therapeutic dose of regdanvimab also reduced the viral load of the SARS-CoV-2 virus and inflammation in the lungs
News
EU approval for self-administered Crysvita
Crysvita is used to treat the rare genetic condition X-linked hypophosphataemia
Roche reveals new safety data for haemophilia treatment Hemlibra
No new safety signals identified with longer-term Hemlibra treatment in adult and adolescent patients
New advice issued on COVID-19 vaccination of children and young people
The UK’s JCVI has advised vulnerable children should be offered Pfizer/BioNTech vaccines
Reacta Biotech raises £2.9m to scale up food allergy clinical diagnostics portfolio
The latest funding round was led by Praetura Ventures with follow-on equity from the Development Bank of Wales
DSRU says more research needed to understand immunocompromised patients’ responses to COVID-19 vaccines
Studies showed immunosuppression appeared to weaken immune responses to COVID-19 vaccines
‘Most comprehensive’ flu vaccination programme in UK history launching for winter 2021
Healthcare providers will offer the flu vaccine to over 35 million people from September 2021
Ledaga recommended by NICE for rare type of lymphoma
Draft guidance recommends Ledaga for early-stage mycosis fungoides-type cutaneous T-cell lymphoma
Report finds almost 100% of people tested positive for antibodies after second vaccine dose
Over 207,337 participants tested themselves for COVID-19 antibodies at home between 12 and 25 May 2021
NICE’s decision not to approve Zytiga ‘frustrating’, says ICR
Zytiga is used for the treatment of newly diagnosed, advanced prostate cancer patients
CMA imposes substantial fines on pharma firms for overcharging the NHS
Competition regulator announces fines totalling £260m relating to the supply of hydrocortisone tablets
Spaces still available in the 2021 Sales Awards
There are still available spaces in the 2021 Sales Awards as we enter the last couple of months for entries.
Galapagos reports early clinical results for SIK inhibitor
Novel drug candidate found to be generally safe and well-tolerated in inflammatory indications
Affinivax, Astellas’ pneumococcal vaccine wins breakthrough therapy status
At the same time, Affinivax and Astellas revealed positive results from the Phase II trial of ASP3772
Cancer Research UK reports ‘most successful financial year’ for its spinouts
Investment raised by its spinouts more than doubled in the last year, the charity has reported
